Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Case Comprehensive Cancer Center
Scripps Health
Celgene
CureOne
Stanford University
Children's Oncology Group
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Tufts Medical Center
Fred Hutchinson Cancer Center